CHIMERIC THERAPEUTICS LIMITED — Director's Dealing 2025

Dec 18, 2025

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

ntroduced 30/9/2001.Ame	nded 01/01/11
	Chimeric Therapeutics Limited (ASX: CHM)
Name of Entity:
	68 638 835 828
ABN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Miles Prince
Date of Last Notice:	21 August 2025

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

	irector” should be disclosed in this part.	irector” should be disclosed in this part.	irector” should be disclosed in this part.
	Direct or Indirect Interest				Direct and Indirect
	Nature of indirect interest(including registered holder)				Director related entity
	Note: Prorelevant i	vide details of the circumstances giving rise to thenterest.
	Date of	change			19 December 2025
	No. of s	ecurities held prior to change
						Shares		Options
					Direct	-		-
					Indirect	4273142		-
						,,
					**Total **	4,273,142		-
					Unlisted Options
	Class
	Number acquired					SharesOptions-16,667,000---16,667,000
						Shares		Options
					Direct	-		16,667,000
					Indirect	-		-
					**Total **	-		16,667,000
	Number disposed					SharesOptions------
						Shares		Options
					Direct		-	-
					Indirect		-	-
					**Total **		-	-

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/ConsiderationNote:If consideration is non-cash, provide details and estimatedvaluation		Nil, see ‘nature of change’ below.	Nil, see ‘nature of change’ below.	Nil, see ‘nature of change’ below.
No. of securities held after change				Options16,667,000-16,667,000
			Shares	Options
		Direct	-	16,667,000
		Indirect	4,273,142	-
		**Total **	4,273,142	16,667,000
Nature of changeExample:on-market trade, off-market trade, exercise of options, issueof securities under dividend reinvestment plan, participationin buy-back		Issue of options as per resolution 4 approvedby shareholders at the Annual GeneralMeeting held on 25 November 2025

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, providedetails and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

Were the interests in the securities or No contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period? If prior written clearance was N/A provided, on what date was this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011